The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Open accessAbstract
BACKGROUND: Calcific aortic stenosis has many characteristics in common with atherosclerosis, including hypercholesterolemia. We hypothesized that intensive lipid-lowering therapy would halt the progression of calcific aortic stenosis or induce its regression. METHODS: In this double-blind, placebo-controlled trial, patients with calcific aortic stenosis were randomly assigned to receive either 80 mg of atorvastatin daily or a matched placebo. Aortic-valve stenosis and calcification were assessed with the use of Doppler echocardiography and helical computed tomography, respectively. The primary end points were change in aortic-jet velocity and aortic-valve calcium score. RESULTS: Seventy-seven patients were assigned to atorvastatin and 78 to placebo, with a median follow-up of 25 months (range, 7 to 36). Serum low-density lipoprotein cholesterol concentrations remained at 130+/-30 mg per deciliter in the placebo group and fell to 63+/-23 mg per deciliter in the atorvastatin group (P<0.001). Increases in aortic-jet velocity were 0.199+/-0.210 m per second per year in the atorvastatin group and 0.203+/-0.208 m per second per year in the placebo group (P=0.95; adjusted mean difference, 0.002; 95 percent confidence interval, -0.066 to 0.070 m per second per year). Progression in valvular calcification was 22.3+/-21.0 percent per year in the atorvastatin group, and 21.7+/-19.8 percent per year in the placebo group (P=0.93; ratio of post-treatment aortic-valve calcium score, 0.998; 95 percent confidence interval, 0.947 to 1.050). CONCLUSIONS: Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression. This study cannot exclude a small reduction in the rate of disease progression or a significant reduction in major clinical end points. Long-term, large-scale, randomized, controlled trials are needed to establish the role of statin therapy in patients with calcific aortic stenosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“several randomized trials showed no effect of statins on haemodynamic progression or AS-related clinical events152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, three randomized clinical trials (RCTs) failed to demonstrate any significant benefit of LDL lowering with statins on the progression of AS152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“Several intervention studies have been performed to test the hypothesis that lipid lowering with statin medications would slow the progression of AS, however the results were generally disappointing152–154.”
From Calcific aortic stenosis (2016) · cites this paper as [152]
The cited source says what the claim attributes to it.
In the citing paper
“randomized controlled trials (RCTs) failed to demonstrate any benefit of statin therapy on retard disease progression6–8.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Several clinical trials evaluating statin therapy in mild to moderate AS failed to demonstrate efficacy in lipid lowering as a strategy to mitigate adverse events in the disease39–41.”
From Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction (2026) · cites this paper as [39]
In the citing paper
“lipid-lowering therapy to delay progression of AS has been evaluated in 3 randomized controlled trials; however, all trials reported no significant benefit.[12][13][14]”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“The SALTIRE (Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression) and ASTRONOMER (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin) trials, which evaluated statin efficacy in AS, were constrained by small sample sizes (n=150 and n=269), 12,13 limited median follow-up periods (25 and 42 months), and a focus on advanced AS stages (mean peak velocity, 3.”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“All of the clinical trials aimed to halt the progression of established AS.”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“Second, we observed similar associations with AVR as a strict procedural outcome, which is particularly meaningful in the context of previous neutral clinical trials of lipid-lowering therapies that used AVR as the study end point.[12][13][14]”
From Rare Genetic Variants in LDLR , APOB , and PCSK9 Are Associated With Aortic Stenosis (2024) · cites this paper as [12]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12% per mmol/L reduction in LDL cholesterol), MI, and vascular death [459,460].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [459]
In the citing paper
“Notably, ischaemic events were reduced by 21% in the SEAS trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
In the citing paper
“Suggestions for an association between aortic stenosis, LDL-C and Lp(a), as well as between cholesterol and increased risk for calcification of bioprosthetic valves, were matched with early observational noncontrolled trials that showed beneficial effects of aggressive lipid lowering in slowing the progression of aortic stenosis. However, this was not confirmed in RCTs. 243,377,378”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
In the citing paper
“Notably, ischaemic events were reduced by 21% in the SEAS trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [377]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Zoghbi, W. A., Enriquez-Sarano, M. L., Foster, E., Grayburn, P. A., Kraft, C. D., Levine, R. A., Nihoyannopoulos, P., Otto, C. M., Quiñones, M. A., Rakowski, H., et al. (2003) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(03)00335-3 · Cited by 4,041
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Clinical Factors Associated With Calcific Aortic Valve Disease
Stewart, B. F., Siscovick, D., Lind, B. K., Gardin, J. M., Gottdiener, J. S., Smith, V. E., Kitzman, D. W., & Otto, C. M. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00563-3 · Cited by 2,029
Applied Mixed Models in Medicine
Brown, H., & Presco, R. (2000) · Technometrics · doi:10.1080/00401706.2000.10485742 · Cited by 1,699
Predictors of Outcome in Severe, Asymptomatic Aortic Stenosis
Rosenhek, R., Binder, T. M., Porenta, G., Lang, I. M., Christ, G., SCHEMPER, M., Maurer, G., & Baumgartner, H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008313430903 · Cited by 1,332
Otto, C. M., Kuusisto, J., Reichenbach, D. D., Gown, A. M., & O’Brien, K. D. (1994) · Circulation · doi:10.1161/01.cir.90.2.844 · Cited by 1,315
Association of Aortic-Valve Sclerosis with Cardiovascular Mortality and Morbidity in the Elderly
Otto, C. M., Lind, B. K., Kitzman, D. W., Gersh, B. J., & Siscovick, D. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410302 · Cited by 1,281
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 1,000
González, I. F., Pinar, J., Ribera, A., Marsal, J. R., Cascant, P., González‐Alujas, T., Evangelista, A., Brotons, C., Moral, I., Permanyer-Miralda, G., et al. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312451238 · Cited by 77
Bicuspid aortic valve: a literature review and its impact on sport activity
Mozzi, P. L. D., Longo, U. G., Galanti, G., & Maffulli, N. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn002 · Cited by 75
Matsumoto, Y., Adams, V., Walther, C., Kleinecke, C., Brugger, P., Linke, A., Walther, T., Mohr, F. W., & Schuler, G. C. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn501 · Cited by 75
van den Hoek, H. L., Bos, W. J. W., de Boer, A., & van de Garde, E. M. W. (2011) · BMJ · doi:10.1136/bmj.d7281 · Cited by 73
Rajamannan, N. M. (2009) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00824.2009 · Cited by 74
Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve Disease
Guauque-Olarte, S., Messika-Zeitoun, D., Droit, A., Lamontagne, M., Tremblay-Marchand, J., Lavoie-Charland, E., Gaudreault, N., Arsenault, B. J., Dubé, M.-P., Tardif, J.-C., et al. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.115.001145 · Cited by 72
Toll-Like Receptors, Inflammation, and Calcific Aortic Valve Disease
García‐Rodríguez, C., Parra‐Izquierdo, I., Castaños‐Mollor, I., López, J., Román, J. A. S., & Crespo, M. S. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00201 · Cited by 79
Lee, S. H., Kim, N., Kim, M., Woo, S.-H., Han, I., Park, J., Kim, K., Park, K. S., Kim, K., Shim, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33202-2 · Cited by 70
Role for Galectin‐3 in Calcific Aortic Valve Stenosis
Sádaba, R., Martínez‐Martínez, E., Arrieta, V., Álvarez, V., Fernández‐Celis, A., Ibarrola, J., Melero, A., Rossignol, P., Cachofeiro, V., & López‐Andrés, N. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004360 · Cited by 70
Valvular calcification and its relationship to atherosclerosis in chronic kidney disease.
Leskinen, Y., Paana, T., Saha, H. H. T., Groundstroem, K., Lehtimäki, T. J., Kilpinen, S., Huhtala, H., & Airaksinen, J. K. E. (2009) · PubMed · Cited by 70
Aortic stenosis and diabetes mellitus: An ominous combination
Banovic, M. D., Athithan, L., & McCann, G. P. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118820657 · Cited by 70
Lee, S. H., & Choi, J. (2016) · Immune Network · doi:10.4110/in.2016.16.1.26 · Cited by 74
Aortic Valve Replacement Should Be Operated on Before Symptom Onset
Carabello, B. A. (2012) · Circulation · doi:10.1161/circulationaha.111.079350 · Cited by 67
Coffey, S., Cox, B., & Williams, M. J. A. (2014) · American Heart Journal · doi:10.1016/j.ahj.2013.12.030 · Cited by 68
Vascular Endothelial Growth Factor–Secreting Mast Cells and Myofibroblasts
Syväranta, S., Helske, S., Laine, M., Lappalainen, J., Kupari, M. M., Mäyränpää, M. I., Lindstedt, K. A., & Kovanen, P. T. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.198267 · Cited by 67
Alberton, M., Wu, P., Druyts, E., Briel, M., & Mills, E. J. (2011) · QJM · doi:10.1093/qjmed/hcr158 · Cited by 67
Lipoprotein(a) is robustly associated with aortic valve calcium
Kaiser, Y., Singh, S. S., Zheng, K. H., Verbeek, R., Kavousi, M., Pinto‐Sietsma, S., Vernooij, M. W., Sijbrands, E. J. G., Boekholdt, S. M., de Rijke, Y. B., et al. (2021) · Heart · doi:10.1136/heartjnl-2021-319044 · Cited by 66
Risk factors for valvular calcification
Chen, H. Y., Engert, J. C., & Thanassoulis, G. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000471 · Cited by 66
Increased Aortic Valve Calcification in Familial Hypercholesterolemia
ten Kate, G.-J. R., Bos, S., Dedic, A., Neefjes, L. A., Kurata, A., Langendonk, J. G., Liem, A., Moelker, A., Krestin, G. P., de Feyter, P. J., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.087 · Cited by 65
Berry, C., Lloyd, S. M., Wang, Y., MacDonald, A., & Ford, I. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs339 · Cited by 64
A Novel Role of Extracellular Nucleotides in Valve Calcification
Osman, L., Chester, A. H., Amrani, M., Yacoub, M. H., & Smolenski, R. T. (2006) · Circulation · doi:10.1161/circulationaha.105.001214 · Cited by 64
Hulin, A., Hego, A., Lancellotti, P., & Oury, C. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00021 · Cited by 71
A Role for MMP-10 (Matrix Metalloproteinase-10) in Calcific Aortic Valve Stenosis
Matilla, L., Roncal, C., Ibarrola, J., Arrieta, V., García-Peña, A., Fernández‐Celis, A., Navarro, A., Álvarez, V., Gainza, A., Orbe, J., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314143 · Cited by 63
Grande-Allen, K. J., Osman, N., Ballinger, M. L., Dadlani, H., Marasco, S., & Little, P. J. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.05.014 · Cited by 67
Do Bisphosphonates Slow the Progression of Aortic Stenosis?
Aksoy, O., Çam, A., Goel, S. S., Houghtaling, P. L., Williams, S., Ruiz‐Rodriguez, E., Menon, V., Kapadia, S. R., Tuzcu, E. M., Blackstone, E. H., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.024 · Cited by 63
Husseini, D. E., Boulanger, M., Fournier, D., Mahmut, A., Bossé, Y., Pîbarot, P., & Mathieu, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053393 · Cited by 63
Weiss, R. M., Lund, D. D., Chu, Y., Brooks, R. M., Zimmerman, K. A., Accaoui, R. N. E., Davis, M. K., Hajj, G. P., Zimmerman, M. B., & Heistad, D. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065201 · Cited by 63
Molecular mechanisms underlying the onset of degenerative aortic valve disease
Hakuno, D., Kimura, N., Yoshioka, M., & Fukuda, K. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0400-9 · Cited by 66
Abdul‐Rahman, T., Lizano-Jubert, I., Garg, N., Talukder, S., López, P. P., Awuah, W. A., Shah, R. M., Chambergo, D., Cantu‐Herrera, E., Farooqi, M., et al. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.06.002 · Cited by 62
Poggio, P., Branchetti, E., Grau, J. B., Lai, E. K., Gorman, R. C., Gorman, J. H., Sacks, M. S., Bavaria, J. E., & Ferrari, G. M. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.303017 · Cited by 62
Newby, D. E., Cowell, S. J., & Boon, N. A. (2006) · Heart · doi:10.1136/hrt.2005.066852 · Cited by 62
Self-citationImpact of Plasma Lp-PLA2 Activity on the Progression of Aortic Stenosis
Capoulade, R., Mahmut, A., Tastet, L., Arsenault, M., Bédard, É., Dumesnil, J. G., Després, J.-P., Larose, É., Arsenault, B. J., Bossé, Y., et al. (2015) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2014.09.016 · Cited by 61
Insights into the use of biomarkers in calcific aortic valve disease.
Beckmann, E., Grau, J. B., Sainger, R., Poggio, P., & Ferrari, G. M. (2010) · PubMed · Cited by 61
Côté, N., Couture, C., Pîbarot, P., Després, J., & Mathieu, P. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02522.x · Cited by 60
The lipid theory in the pathogenesis of calcific aortic stenosis
Parisi, V., Leosco, D., Ferro, G., Bevilacqua, A., Pagano, G., de Lucia, C., Filardi, P. P., Caruso, A., Rengo, G., & Ferrara, N. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.02.001 · Cited by 60
Linefsky, J. P., O’Brien, K. D., Sachs, M. C., Katz, R., Eng, J., Michos, E. D., Budoff, M. J., de Boer, I. H., & Kestenbaum, B. R. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.051 · Cited by 60
Speidl, W. S., Cimmino, G., Ibáñez, B., Elmariah, S., Hutter, R., Garcia, M. J., Fuster, V., Goldman, M. E., & Badimón, J. J. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq064 · Cited by 60
Yip, C. Y. Y., Blaser, M. C., Mirzaei, Z., Zhong, X., & Simmons, C. A. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.223974 · Cited by 60
Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments
Myasoedova, V. A., Ravani, A. L., Frigerio, B., Valerio, V., Moschetta, D., Songia, P., & Poggio, P. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.020 · Cited by 62
Risk factors for progression of calcific aortic stenosis and potential therapeutic targets
Kamath, A., & Pai, R. G. (2011) · International Journal of Angiology · doi:10.1055/s-0031-1278283 · Cited by 60
Regression of aortic valve stenosis by ApoA‐I mimetic peptide infusions in rabbits
Busseuil, D., Shi, Y., Mecteau, M., Brand, G., Kernaleguen, A., Thorin, É., Latour, J.-G., Rhéaume, É., & Tardif, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.122 · Cited by 60
Insights into aortic sclerosis and its relationship with coronary artery disease
Milin, A. C., Vorobiof, G., Aksoy, O., & Ardehali, R. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001111 · Cited by 59
Skowasch, D., Schrempf, S., Preusse, C. J., Likungu, J. A., Welz, A., Lüderitz, B., & Bauriedel, G. (2005) · Heart · doi:10.1136/hrt.2005.069815 · Cited by 59
Ramaraj, R., & Sorrell, V. L. (2008) · BMJ · doi:10.1136/bmj.39478.498819.ad · Cited by 59
Pathogenesis of aortic stenosis: not just a matter of wear and tear.
Sverdlov, A. L., Ngo, D. T. M., Chapman, M., Ali, O. A., Chirkov, Y. Y., & Horowitz, J. D. (2011) · Europe PMC (PubMed Central) · Cited by 58
Treatment Options in Severe Aortic Stenosis
Bates, E. (2011) · Circulation · doi:10.1161/circulationaha.110.974204 · Cited by 58
Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves
Helske, S., Miettinen, T. A., Gylling, H., Mäyränpää, M. I., Lommi, J., Turto, H., Werkkala, K., Kupari, M. M., & Kovanen, P. T. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800058-jlr200 · Cited by 58
Kurtz, C. E., & Otto, C. M. (2010) · Medicine · doi:10.1097/md.0b013e3181fe5648 · Cited by 58
Drug Therapy for Heart Valve Diseases
BORER, J. S., & Sharma, A. (2015) · Circulation · doi:10.1161/circulationaha.115.016006 · Cited by 55
Broeders, W., Bekkering, S., Messaoudi, S. E., Joosten, L. A. B., van Royen, N., & Riksen, N. P. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00935-6 · Cited by 57
Quang, K. L., Bouchareb, R., Lachance, D., Laplante, M., Husseini, D. E., Boulanger, M., Fournier, D., Fang, X. P., Avramoglu, R. K., Pîbarot, P., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304205 · Cited by 55
Cells of primarily extravalvular origin in degenerative aortic valves and bioprostheses
Skowasch, D., Schrempf, S., Wernert, N., Steinmetz, M., Jabs, A., Tuleta, I., WELSCH, U. N., Preusse, C. J., Likungu, J., Welz, A., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi458 · Cited by 55
Morbelli, S. D., Fiz, F., Piccardo, A., Picori, L., Massollo, M., Pestarino, E., Marini, C., Cabria, M., Democrito, A., Cittadini, G., et al. (2013) · International journal of cardiac imaging · doi:10.1007/s10554-013-0342-3 · Cited by 54
Nathaniel, S. (2010) · World Journal of Cardiology · doi:10.4330/wjc.v2.i6.135 · Cited by 54
Determinants of Occurrence of Aortic Sclerosis in an Aging Population
Ngo, D. T. M., Sverdlov, A. L., Willoughby, S. R., Nightingale, A. K., Chirkov, Y. Y., McNeil, J. J., & Horowitz, J. D. (2009) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2009.03.016 · Cited by 54
Assessment of risk factors for developing incident aortic stenosis: the Tromsø Study
Eveborn, G. W., Schirmer, H., Lunde, P., Heggelund, G., Hansen, J., & Rasmussen, K. (2014) · European Journal of Epidemiology · doi:10.1007/s10654-014-9936-x · Cited by 54
Severe Aortic Stenosis Should Not Be Operated on Before Symptom Onset
Shah, P. K. (2012) · Circulation · doi:10.1161/circulationaha.111.079368 · Cited by 54
Imai, K., Okura, H., Kume, T., Yamada, R., Miyamoto, Y., Kawamoto, T., Watanabe, N., Neishi, Y., Toyota, E., & Yoshida, K. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.04.011 · Cited by 54
Sung, D. C., Bowen, C. J., Vaidya, K. A., Zhou, J., Chapurin, N., Recknagel, A. K., Zhou, B., Chen, J., Kotlikoff, M. I., & Butcher, J. T. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307812 · Cited by 56
Relation of Circulating C-Reactive Protein to Progression of Aortic Valve Stenosis
Sanchez, P. L., dos Santos, J. L. V., Kaski, J. C., Cruz‐González, I., Arribas, A., Villacorta, E., Cascón, M., Palacios, I. F., & Martín‐Luengo, C. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.113 · Cited by 54
Mohty, D., Pibarot, P., Després, J.-P., Cartier, A., Arsenault, B., Picard, F., & Mathieu, P. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.12.068 · Cited by 53
Hekimian, G., Boutten, A., Flamant, M., Duval, X., Dehoux, M., Benessiano, J., Huart, V., Dupré, T., Berjeb, N., Tubach, F., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs450 · Cited by 53
The role of statins in clinical medicine -LDL - cholesterol lowering and beyond
Rutishauser, J. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11170 · Cited by 53
Anesthetic Considerations in the Patient With Valvular Heart Disease Undergoing Noncardiac Surgery
Mittnacht, A. J. C., Fanshawe, M., & Konstadt, S. N. (2008) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253208316442 · Cited by 53
Combination therapy in dyslipidemia: Where are we now?
Catapano, A. L., Farnier, M., Foody, J. M., Toth, P. P., Tomassini, J. E., Brudi, P., & Tershakovec, A. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.026 · Cited by 52
Trion, A., Schutte, C. I., Bax, W. H., Jukema, J. W., & van der Laarse, A. (2007) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-007-9608-1 · Cited by 52
Lin, C.-P., Huang, P., Lai, C. F., Chen, J., Lin, S., & Chen, J.-S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143686 · Cited by 52
Lipoprotein(a) and calcific aortic valve stenosis: A systematic review
Guddeti, R. R., Patil, S., Ahmed, A., Sharma, A., Aboeata, A., Lavie, C. J., & Alla, V. M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.06.002 · Cited by 52
Awan, Z. A., Denis, M., Roubtsova, A., Essalmani, R., Marcinkiewicz, J., Awan, A., Gram, H., Seidah, N. G., & Genest, J. J. (2015) · Angiology · doi:10.1177/0003319715583205 · Cited by 51
van der Linde, D., Yap, S., van Dijk, A. P. J., Budts, W., Pieper, P. G., van der Burgh, P. H., Mulder, B. J. M., Witsenburg, M., Cuypers, J. A. A. E., Lindemans, J. W., et al. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.032 · Cited by 51
Monzack, E. L., Gu, X., & Masters, K. S. B. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179218 · Cited by 51
Chen, J., Lin, Y., & Sun, Z. (2016) · Aging Cell · doi:10.1111/acel.12494 · Cited by 52
Lindman, B. R., Arnold, S. V., Bagur, R., Clarke, L., Coylewright, M. J., Evans, F., Hung, J., Lauck, S., Peschin, S., Sachdev, V., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015975 · Cited by 51
Effect of Bisphosphonates on the Progression of Degenerative Aortic Stenosis
Innasimuthu, A. L., & Katz, W. E. (2010) · Echocardiography · doi:10.1111/j.1540-8175.2010.01256.x · Cited by 52
Chan, K., Teo, K. K., Tam, J. W., & Dumesnil, J. G. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.03.011 · Cited by 51
Poggio, P., Sainger, R., Branchetti, E., Grau, J. B., Lai, E. K., Gorman, R. C., Sacks, M. S., Parolari, A., Bavaria, J. E., & Ferrari, G. M. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt055 · Cited by 52
The Relationship between Neutrophil/Lymphocyte Ratio and Calcific Aortic Stenosis
Avcı, A., Alızade, E., Göksel, A., Fidan, S., İzcı, S., Koyuncu, A., Tabakçı, M. M., Cuneyt, T., Güler, Y., Mustafa, B., et al. (2014) · Echocardiography · doi:10.1111/echo.12534 · Cited by 50
Calcific aortic valve disease: Is it another face of atherosclerosis?
Sathyamurthy, I., & Alex, S. (2015) · Indian Heart Journal · doi:10.1016/j.ihj.2015.07.033 · Cited by 53
Mrsic, Z., Hopkins, S., Antevil, J. L., & Mullenix, P. S. (2017) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2017.10.002 · Cited by 50
Jassal, D. S., Tam, J. W., Bhagirath, K. M., Gaboury, I., Sochowski, R. A., Dumesnil, J. G., Giannoccaro, P. J., Jue, J., Pandey, A. S., Joyner, C. D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn172 · Cited by 50
The Year in Valvular Heart Disease
Rahimtoola, S. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.11.022 · Cited by 50
ApoC-III is a novel inducer of calcification in human aortic valves
Schlotter, F., de Freitas, R. C. C., Rogers, M. A., Blaser, M. C., Wu, P.-J., Higashi, H., Halu, A., Iqbal, F., Andraski, A. B., Rodia, C. N., et al. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015700 · Cited by 49
Pioglitazone attenuates valvular calcification induced by hypercholesterolemia
Chu, Y., Lund, D. D., Weiss, R. M., Brooks, R. M., Doshi, H., Hajj, G. P., Sigmund, C. D., & Heistad, D. D. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300794 · Cited by 49
Valve Calcification in Aortic Stenosis: Etiology and Diagnostic Imaging Techniques
Izquierdo‐Gómez, M. M., Hernández-Betancor, I., García‐Niebla, J., Marí‐López, B., Laynez‐Cerdeña, I., & Lacalzada-Almeida, J. B. (2017) · BioMed Research International · doi:10.1155/2017/5178631 · Cited by 54
Lipoprotein(a): Emerging insights and therapeutics
Kaur, G., Abdelrahman, K., Berman, A. N., Biery, D. W., Shiyovich, A., Huck, D. M., Garshick, M. S., Blankstein, R., & Weber, B. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100641 · Cited by 49
Calcific Aortic Stenosis—A Review on Acquired Mechanisms of the Disease and Treatments
Zebhi, B., Lazkani, M., & Bark, D. L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.734175 · Cited by 49
Modified Lipoprotein-Derived Lipid Particles Accumulate in Human Stenotic Aortic Valves
Lehti, S., Käkelä, R., Hörkkö, S., Kummu, O., Suihko, S., Kupari, M. M., Werkkala, K., Kovanen, P. T., & Öörni, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065810 · Cited by 48
Vascular Calcification: A Perspective On An Imminent Disease Epidemic
Towler, D. A. (2008) · IBMS BoneKEy · doi:10.1138/20080298 · Cited by 48
Stewart, R., Kerr, A., Cowan, B. R., Young, A. A., Occleshaw, C. J., Richards, M., Edwards, C. C., WHALLEY, G. A., Freidlander, D., Williams, M., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.03.012 · Cited by 48
Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors
Lippi, G., Favaloro, E. J., & Sanchis‐Gomar, F. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0033-1343892 · Cited by 47
Xu, S., Liu, C. A., & Gotlieb, A. I. (2009) · Cardiovascular Pathology · doi:10.1016/j.carpath.2009.09.007 · Cited by 47
Visualizing novel concepts of cardiovascular calcification
Hjortnaes, J., New, S. E. P., & Aïkawa, E. (2013) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2012.09.003 · Cited by 51
Calcific Aortic Valve Stenosis and Atherosclerotic Calcification
Sá, M. P., Cavalcanti, L. R. P., Perazzo, Á., Gomes, R. A. F., Clavel, M.-A. A., Pîbarot, P., Biondi‐Zoccai, G., Zhigalov, K., Weymann, A., Ruhparwar, A., et al. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0821-7 · Cited by 47
Mosch, J., Gleissner, C. A., Body, S. C., & Aïkawa, E. (2017) · PubMed · doi:10.14670/hh-11-797 · Cited by 48
The role of stress concentration in calcified bicuspid aortic valve
Qin, T., Caballero, A., Mao, W., Barrett, B., Kamioka, N., Lerakis, S., & Sun, W. (2020) · Journal of The Royal Society Interface · doi:10.1098/rsif.2019.0893 · Cited by 46
Aortic Stenosis Progression, Cardiac Damage, and Survival
Yang, L., Boler, A. N., Medina‐Inojosa, J. R., Scott, C. G., Maurer, M. J., Eleid, M. F., Enriquez-Sarano, M. L., Tribouilloy, C., & Michelena, H. I. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.01.017 · Cited by 46
Calcific aortic stenosis: omics-based target discovery and therapy development
Blaser, M. C., Bäck, M., Lüscher, T. F., & Aikawa, E. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehae829 · Cited by 45
Wu, H. D., Maurer, M. S., Friedman, R. A., Marboe, C. C., Ruiz-Vazquez, E. M., Ramakrishnan, R., Schwartz, A. J., Tilson, M. D., Stewart, A. S., & WINCHESTER, R. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.5329 · Cited by 45
Štěrbáková, G., Vyskočil, V., & Linhartová, K. (2010) · Cardiology · doi:10.1159/000321418 · Cited by 45
Pasipoularides, A. D. (2016) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-016-9679-z · Cited by 47
Metadata
- Authors
- Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A.
- Affiliations
- Edinburgh Royal Infirmary (GB)
- University of Edinburgh (GB)
- Borders General Hospital (GB)
- Western General Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-09
- Volume
- 352
- Issue
- 23
- Pages
- 2389-2397
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2117330772
- Cited by
- 1,146
- References
- 41
- Citations by year
- 2026: 46 · 2025: 52 · 2024: 57 · 2023: 37 · 2022: 47 · 2021: 44 · 2020: 59 · 2019: 38 · 2018: 39 · 2017: 52 · 2016: 52 · 2015: 37 · 2014: 65 · 2013: 64 · 2012: 55
- FWCI
- 47.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Keywords
- calcific aortic stenosis, atorvastatin, statin therapy, lipid-lowering therapy, valve calcification, disease progression, aortic jet velocity, aortic valve calcium score, LDL cholesterol, hypercholesterolemia, atherosclerosis, echocardiography, CT angiography
- MeSH terms
- Atorvastatin, Anticholesteremic Agents, Aortic Valve, Aortic Valve Stenosis, Blood Flow Velocity, Calcinosis, Double-Blind Method, Heptanoic Acids, Humans, Cholesterol, LDL, Pyrroles, Echocardiography, Doppler, Treatment Failure, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
